HK1109636A1 - Human antibodies and proteins - Google Patents

Human antibodies and proteins

Info

Publication number
HK1109636A1
HK1109636A1 HK08103899.8A HK08103899A HK1109636A1 HK 1109636 A1 HK1109636 A1 HK 1109636A1 HK 08103899 A HK08103899 A HK 08103899A HK 1109636 A1 HK1109636 A1 HK 1109636A1
Authority
HK
Hong Kong
Prior art keywords
variable regions
proteins
human antibodies
composite antibody
antibody variable
Prior art date
Application number
HK08103899.8A
Other languages
English (en)
Inventor
Timothy David Jones
Matthew Paul Baker
Original Assignee
Antitope Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0502201A external-priority patent/GB0502201D0/en
Priority claimed from GB0503190A external-priority patent/GB0503190D0/en
Priority claimed from GB0506945A external-priority patent/GB0506945D0/en
Application filed by Antitope Ltd filed Critical Antitope Ltd
Publication of HK1109636A1 publication Critical patent/HK1109636A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK08103899.8A 2005-02-03 2008-04-08 Human antibodies and proteins HK1109636A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0502201A GB0502201D0 (en) 2005-02-03 2005-02-03 Human antibodies
GB0503190A GB0503190D0 (en) 2005-02-16 2005-02-16 Human antibodies
GB0506945A GB0506945D0 (en) 2005-04-05 2005-04-05 Human antibodies
PCT/GB2006/000355 WO2006082406A2 (en) 2005-02-03 2006-02-03 Human antibodies and proteins

Publications (1)

Publication Number Publication Date
HK1109636A1 true HK1109636A1 (en) 2008-06-13

Family

ID=36777595

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103899.8A HK1109636A1 (en) 2005-02-03 2008-04-08 Human antibodies and proteins

Country Status (11)

Country Link
US (4) US20080206239A1 (de)
EP (2) EP2388271A3 (de)
JP (4) JP2008528668A (de)
KR (1) KR101385886B1 (de)
CN (1) CN101115771B (de)
AU (1) AU2006210724A1 (de)
CA (1) CA2596833C (de)
DK (1) DK1844074T3 (de)
ES (1) ES2417133T3 (de)
HK (1) HK1109636A1 (de)
WO (1) WO2006082406A2 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
PT1737961E (pt) 2004-03-19 2013-08-26 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
CA2822302A1 (en) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2008044032A2 (en) * 2006-10-11 2008-04-17 Antitope Limited T cell epitope databases
AU2016203577B2 (en) * 2007-01-30 2017-12-21 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
EP2423221B1 (de) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatorische t-zellen-epitope sowie zusammensetzungen damit und anwendungen davon
WO2009023185A1 (en) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
EP3753947A1 (de) 2007-09-14 2020-12-23 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
SI2342226T1 (sl) * 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
WO2010113148A1 (en) 2009-03-30 2010-10-07 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation
KR20110138412A (ko) * 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2473531A4 (de) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr-antikörper
CN102740877B (zh) 2009-09-06 2015-01-14 普罗塔布有限公司 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途
WO2011069019A2 (en) * 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
CA2915412A1 (en) 2012-06-14 2013-12-19 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
MX2015000863A (es) 2012-07-19 2016-05-05 Alethia Biotherapeutics Inc Anticuerpos anti-siglec-15.
KR102165464B1 (ko) 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
EP2895197B1 (de) 2012-09-12 2020-02-26 Ramot at Tel-Aviv University Ltd. Immunpartikel, verfahren zu deren herstellung, und deren verwendung
RS57694B1 (sr) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pirolobenzodiazepin - anti-psma konjugati antitela
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
MX364327B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
BR112015008251B1 (pt) 2012-10-12 2023-09-26 Medimmune Limited Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
HUE039329T2 (hu) 2012-10-12 2018-12-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
MX2015008534A (es) 2012-12-26 2017-07-04 Oncosynergy Inc COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102531517B1 (ko) * 2013-07-05 2023-05-12 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017006770A (es) 2014-11-25 2018-02-09 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
CN107531777A (zh) * 2015-01-21 2018-01-02 英伊布里克斯有限合伙公司 非免疫原性单结构域抗体
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
KR20180050321A (ko) 2015-08-07 2018-05-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3445785B1 (de) 2016-04-18 2022-06-22 Faron Pharmaceuticals OY Humanisierte anti-clever-1-antikörper und deren verwendung
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US11708421B2 (en) 2016-07-18 2023-07-25 Ramot At Tel-Aviv University Ltd. Modular platform for targeted therapeutics
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3544636T (pt) 2017-02-08 2021-05-04 Medimmune Ltd Conjugados de anticorpos-pirrolobenzodiazepinas
EP3939616A1 (de) 2017-02-08 2022-01-19 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
ES2906965T3 (es) 2017-08-18 2022-04-21 Medimmune Ltd Conjugados de pirrolobenzodiazepina
CN111757893A (zh) * 2018-01-05 2020-10-09 伊穆奈克斯特股份有限公司 抗mct1抗体及其用途
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
EP3972644A4 (de) * 2019-05-21 2024-01-10 Univ California Mmp-9-antikörper und verfahren zur verwendung davon
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202208427A (zh) * 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
GB202015226D0 (en) 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
WO2024052684A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Antibody drug conjugate comprising nmt inhibitor and its use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0528767B1 (de) * 1991-08-21 2000-01-12 Novartis AG Antikörperderivate
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES2258817T3 (es) * 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
WO1999011777A1 (en) 1997-09-03 1999-03-11 Biovation Limited Methods for protein screening
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
ATE352559T1 (de) * 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
CA2438652A1 (en) * 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
CN1585778A (zh) 2001-11-12 2005-02-23 默克专利有限公司 修饰的抗－TNFα抗体
WO2004113386A2 (en) 2003-06-26 2004-12-29 Merck Patent Gmbh Modified hirudin proteins and t-cell epitopes in hirudin
PT1737961E (pt) 2004-03-19 2013-08-26 Merck Patent Gmbh Proteínas buganina modificadas, citotoxinas e métodos e utilizações das mesmas
AU2006210724A1 (en) * 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
WO2006124866A2 (en) * 2005-05-13 2006-11-23 The Johns Hopkins University Free human serum ige immunoenzymetric assay and methods of use
JP5538278B2 (ja) * 2011-03-22 2014-07-02 株式会社ジャパンディスプレイ 液晶表示素子の製造方法および液晶表示素子
JP6054630B2 (ja) * 2012-05-18 2016-12-27 ヤマト包装技術研究所株式会社 物品拘束具、ロールボックスパレット及び物品の固定方法

Also Published As

Publication number Publication date
DK1844074T3 (da) 2013-07-15
CA2596833C (en) 2016-04-12
US20150031550A1 (en) 2015-01-29
CN101115771A (zh) 2008-01-30
KR20070107739A (ko) 2007-11-07
CN101115771B (zh) 2013-06-05
JP2013028616A (ja) 2013-02-07
WO2006082406A2 (en) 2006-08-10
WO2006082406A3 (en) 2007-02-01
US20150031860A1 (en) 2015-01-29
JP2008528668A (ja) 2008-07-31
EP2388271A2 (de) 2011-11-23
EP2388271A3 (de) 2012-08-01
ES2417133T3 (es) 2013-08-06
AU2006210724A1 (en) 2006-08-10
KR101385886B1 (ko) 2014-04-24
EP1844074A2 (de) 2007-10-17
US20170210820A1 (en) 2017-07-27
CA2596833A1 (en) 2006-08-10
US20080206239A1 (en) 2008-08-28
JP2016210782A (ja) 2016-12-15
EP1844074B1 (de) 2013-04-24
JP5461643B2 (ja) 2014-04-02
JP2014073128A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
HK1109636A1 (en) Human antibodies and proteins
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
WO2006104677A3 (en) Antibodies that bind ov064 and methods of use therefor
WO2007047112A3 (en) Anti-myostatin antibodies
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
SG170793A1 (en) Anti-mn antibodies and methods of using same
TW200510459A (en) RG1 antibodies and uses thereof
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
BRPI0608342A2 (pt) antìgenos recombinantes quiméricos de toxoplasma gondii
WO2010043977A3 (en) Dengue virus neutralizing antibodies and uses thereof
EP2332970A3 (de) Mutierte Pseudomonas exotoxine mit reduzierter antigenizität
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
WO2006138509A3 (en) Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2006125201A3 (en) Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
MX2010001237A (es) Nuevos anticuerpos.
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2006032216A3 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
WO2005051999A3 (en) Substance binding human igg fc receptor iib
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4
WO2003106478A3 (en) ANTIBODIES BINDING TO ALPHAE INTEGRIN
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200201